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The heat shock response was first identified in 1962 when
Ritossa described the formation of chromosome puffs in the
salivary glands of the fruitfly Drosophila bucksii subjected to
temperature elevation, sodium salicylate or dinitrophenol
(Ritossa, 1962). However it was not until 1973 that Tissieres
demonstrated that these 'puffing' patterns corresponded with
the synthesis of a group ofproteins, which he named the heat
shock proteins (hsps) (Tissieres et al., 1974).
Since then it has been demonstrated that many types of
stresses can induce increased synthesis of these proteins
resulting in them often being referred to as stress proteins. It
has been shown that some of these proteins are constitutively
expressed whereas others are inducible by stress; and that
they play critical roles in the cell in the unstressed state. In
particular, they function in chaperoning proteins of the cell
ensuring that they are maintained in their correct state of
folding under normal conditions (for review see Lindquist
1986, 1988; Creighton, 1990; Latchman, 1991).
The hsps have been classified into families based upon
their molecular weight (MW). In mammals these are hsplOO,
hsp90, hsp70, hsp60, the 22-32 kDa hsps and ubiquitin
which has a molecular weight of 7-8 kDa (Table I).
Some members of the hsp70, hsp27 and hsp90 families
have been suggested to play a defined role in cancer. The
potential role of each of these hsps will be discussed with
special reference to breast cancer where this role has been
particularly studied.
Expression of hsps in breast cancer
Hsp27
Hsp27 has been isolated by different laboratories as a 25 kDa
protein associated with actin polymerisation, P24, an
oestrogen-associated protein and as a 25 kDa growth-related
protein (Ciocca et al., 1993a; Miron et al., 1991). Hsp27 was
initially identified as an oestrogen-binding protein in human
breast cancer cell lines (Edwards et al., 1981). Hsp27
expression has been studied extensively in breast carcinoma,
where overexpression of hsp27 has been associated with
shorter disease-free survival (DFS) in patients with local
disease, although it does not provide prognostic value
independent of other indicators such as the presence of
disease that has spread to the lymph nodes (Thor et al.,
1991). Another study investigated immunohistochemical
analysis of tumours in patients (n=361) with primary breast
cancer in relation to disease-free survival, survival from first
relapse and oestrogen and progesterone receptor status (Love
and King, 1994). Patients with tumours positive for hsp27
had a prolonged survival from first relapse but short DFS.
This association with short DFS was only true in patients
with no nodal involvement and agreed with data published
elsewhere (Tandon et al., 1991). Hsp27 has also been shown
to predict for hormone sensitivity of advanced breast cancers
(Love and King, 1994).
There have also been several studies examining hsp27
expression and both drug and multidrug resistance in breast
cancer cells (Oesterreich et al., 1993; Ciocca, 1992).
Transfections of breast cancer cells that usually have low
levels of hsp27, with a full length hsp27 construct resulted in
3-fold elevated resistance to doxorubicin. When these cells
were transfected with an anti-sense hsp27 construct, they
were rendered sensitive to doxorubicin. It is possible the hsp
functions to enable the cell to recover from damage induced
by the drug, such as by interacting with proteins essential for
the cell cycle.
It is of considerable interest to compare these data with
those obtained in other tumour cell types. Thus hsp27
expression was studied in patients with neuroblastoma
(n=53) and in 17 neuroblastoma cell lines to investigate the
relationship between hsp27 expression, stage of disease and
N-myc copy number (Ungar et al., 1994). Increased hsp27
expression in neuroblastomas was associated with limited
stage disease and inversely correlated with N-myc gene
amplification, a feature known to predict poor clinical
outcome. An inverse correlation was also observed between
N-myc gene amplification and hsp27 protein levels among the
neuroblastoma cell lines analysed. Immunohistochemical
staining of sections of neuroblastomas showed that hsp27
was expressed most prominently in the cytoplasm of large
ganglionic tumour cells present in neuronally differentiated
areas of the tumours. Interestingly, differentiation of
neuroblastoma cell lines using retinoic acid resulted in
increased expression of hsp27. Retinoic acid decreases N-
myc expression and cellular proliferation (Thiele et al., 1985).
Thus, it is likely that there may be some interrelationship
between N-myc and hsp27 protein levels and differentiation
and proliferation status of neuroblastoma cells.
In malignant fibrous histocytoma, hsp27 expression is
associated with longer survival (Tetu et al., 1992). In
addition, patients who developed metastatic disease were
more likely to respond to chemotherapy if their tumours
expressed hsp27. This contrasts to the in vitro data in breast
cells which suggest that hsp27 expression is associated with
resistance to chemotherapeutic drugs. Thus, high levels of
hsp27 can be associated with both a good prognosis in some
malignancies and a poor prognosis in others. This could
indicate that hsp27 has different roles in different tissues or
that there are other elements present in some malignancies
that can override or bypass the effect of hsp27. Hsp27 might
serve as an intrinsic marker of tumour cells with different
degrees of phosphorylation of hsp27 relating to drug
resistance.
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Table I The classification of heat shock proteins
Size
Family Members (kDa) Functions/Comments
hsp 110 hspl 0, hsplO4 80-110 Extreme heat tolerance
ATPase activity
hsp90 hsplOO, (gp96, 82-100 Cytoplasmic proteins associated
grp94), hsp90a with steroid receptors, protein
hsp9O0, kinases, immunophilins
Possible role in protein synthesis
Weak chaperone activity
hsp70 Several, including 67-76 Blind unfolded proteins and
hsp72, (hsp70, peptides involved in cell cycle
hsx70), hsp73 regulation, protein assembly,
(hsc70), grp78 secretion, thermotolerance
(BiP), grp75 Associates with hsp90 and steroid
receptors weak ATPase activity
hsp60 hsp60 (hsp65 58 -65 Found in mitochondria
hsp58 Molecular chaperones
chaperonin 60) Temperature-regulated ATPase activity
Small hsp27 (hsp28, 18-27 hsp27 contributes to
hsps hsp29, hsp26 thermotolerance in mammals
hsp23, hsp22) hsps 27 is structurally related to
hspl8, a-crystallin
hsplO hsplO, GroES 9-12 Stimulates Hsp6O functions
ATP-binding ability
Ubiquitin Ubiquitin 8 Targets abnormal proteins for
degradation
Other FKBP59 hsp56 associates with steroid
hsps (hsp56), hsp47, receptors
hsp32 (haemoxygenase) Peptidyl prolyl isomerase (PPI)
Unknown stress functions
Hsp7O
There are several lines of evidence for the involvement of
hsp70 in breast cancer. Expression of hsp70 in breast cancer
tissue has been examined using Western blotting in patients
with negative axillary lymph nodal status (n =345) (Ciocca et
al., 1993b). Patients whose tumour had high expression of
hsp70 had significantly shorter disease-free survival, and in
patients who had undergone chemotherapy, hsp70 was the
only independent predictor of disease survival. It is possible
that the increased hsp70 might arise as a result of stress
caused by anoxia or nutrient deprivation. Hsp7O is thought
to be involved in chaperoning the c-myc oncogene and p53
tumour-suppressor gene products so that its elevated
expression could be as a result of mechanisms for tumour
cell transformation or progression (Pinhasi-Kimhi et al.,
1986). Interestingly, mutation of the p53 gene has been
demonstrated to cause conformational changes in the p53
protein which leads to the formation of a complex with
hsp70. In vivo studies have been undertaken to investigate
whether p53 that occurs in the nucleus of human cancer cells
is bound to hsp70 using immunohistochemical localisation of
both p53 and hsp70 in breast cancer tumours. There was a
weak but significant correlation between localisation of the
two proteins, but where there was a p53 mutation a p53-
hsp70 complex was readily detected (Iwaya et al., 1995).
The immune response to p53 has been shown to be
dependent upon p53 -hsp70 complexes in breast cancer
(Davidoff et al., 1992). Between 10 and 25% of patients
with breast cancer have been reported as having circulating
antibodies directed against p53 protein (Crawford et al.,
1982; Vojtesek et al., 1995). All antibody-eliciting tumours
contained complexes between p53 and hsp70, which implies
that hsp7o may be involved in the antigenic presentation of
p53. These results suggest that mutant p53 protein which
complexes with hsp70 in breast cancer induces a p53-specific
humoral response. One possibility is that association of p53
with hsp70 in the tumour itself could present p53 to the
immune system. In support of this a 70 kDa peptide-binding
protein that is important in antigen processing and
presentation has been shown to be hsp73. Additional
evidence for the involvement of hsp70 in breast cancer
arises from studies showing human tumour-infiltrating CD4+
T cells are able to react with B cells expressing hsp70
(Moshino et al., 1994).
Hsp9O
The association of hsp90 and breast cancer is of considerable
interest, following studies showing the association of hsp90
and steroid receptors (Pratt, 1987; Shyamala et al., 1989).
Hsp9O exists as two isoforms, hsp90a and hsp9O# (also
known as hsp89o and hsp89/3, sharing a high degree of
homology. The expression of hsp89a has been investigated in
human breast cancer tissue (Jameel et al., 1992, 1993). The
authors isolated a cDNA clone, AJ1, by immunoscreening a
human breast tumour library with a polyclonal anti-serum
raised against breast cancer metastasis membranes. AJ1
showed complete homology with human hsp89a. The level
of AJI was then studied in human benign breast tissue
(n = 17), breast cancer (n = 143) and various breast cancer cell
lines (n= 5). All tissues were found to have some expression
of AJI but there were significantly higher amounts of AJI in
malignant breast tissue compared with healthy breast tissue.
No significant correlation was found between AJI expression
and menopausal status, ER (oestrogen receptor) status,
clinical or histological size or tumour grade. However, there
was significant association between high AJI levels and
histological node involvement. Short-term survival was
increased in patients with low levels of AJ1, up to 11 years.
AJ1 was also expressed constitutively in several breast cancer
cell lines and also in a 'normal' breast cell line. Heat shock
was found to induce AJ1 and AJ1 levels were increased by
oestrogen and growth factors, but blocked by tamoxifen or
cycloheximide. Patients with ovarian cancer have also been
reported as having increased expression of total hsp90
mRNA (Mileo et al., 1990). Patients with more advanced
disease had higher levels, although there was no associationbetween the levels of hsp9o mRNA and either oestrogen or
progesterone receptor status. More recently, the expression of
hsp9o has been examined in patients with endometrial cancer
(Nanbu et al., 1996). Hsp9O was detected at high levels in
25% of endometrial carcinomas and occurred more
frequently in well-differentiated carcinomas that were
positive for steroid receptors.
Immune responses to hsps in cancer
Antibodies to human purified hsp9o have been detected by
ELISA in a significant proportion (37%) of patients with
breast cancer (Conroy et al., 1995). The presence of these
antibodies was found to be correlated with the development
of metastases even in patients without axillary nodal
involvement. One explanation for the presence of anti-hsp90
antibodies in patients with breast cancer might be that the
hsp90 is transporting peptides onto the cell surface leading to
the generation of antibodies against them. Another explana-
tion for the presence of antibodies to hsp9o being detected at
higher frequency in those patients who were more likely to go
on to develop metastasis might be that more cells are
transporting peptides of hsp9o to the cell surface. Alter-
natively, it is possible that the movement of the cancer cell
from the breast to site of metastases results in exposure of the
antigen to the immune system, which might explain why the
antibodies were found in patients who subsequently went on
to exhibit metastases. It would be of considerable interest to
investigate whether there is an immune response to hsp70 or
hsp27 in patients with breast cancer and whether this
response correlates with expression of the heat shock
proteins as well as clinical parameters.
Hsp7O and hsp90 have been located on cell surfaces of
tumour cells and tumour cell lines (Tsuboi et al., 1994;
Ferrarini et al., 1992; Konno et al., 1989; Multhoff et al.,
1995). As there is no structural difference between the hsps in
or on tumour cells and those expressed by normal cells the
question is how these cytosolic proteins become expressed on
the cell surface if they lack sequences for cell surface
translocation. It is possible that anti-hsp antibodies cross-
react with structurally similar epitopes on unrelated surface
molecules; although several immunoprecipitation experiments
suggest that the precipitated surface molecules are indeed
hsps. Alternatively, hsps could be translocated to the cell
surface by unknown mechanisms; hsp7o could be translo-
cated passively by unrelated cell surface proteins. The
localisation of hsp9o and hsp70 to the surface of tumour
cells, in contrast to their normal intracellular location,
suggests a role as markers of tumour cells. Another
possibility is that they are released by adjacent dying cells
and absorbed onto the surface of intact cells.
It has been demonstrated that inbred mice and rats
immunised against their own tumours or tumours of the same
genetic background become immune to challenges with
tumour cells (Srivastava and Old, 1988). These studies
demonstrated that mice vaccinated with inactive cancer cells
become immune to subsequent challenges with live cancer
cells. This response was tumour-specific in that mice became
immune to the tumours that were used to immunise them and
not to other tumours.
This led to the concept of immunogenicity, and the search
for cancer-derived molecules which elicited resistance to
tumour challenges. The general approach used was to take
fractionated cancer cell-derived proteins and test them
individually for their ability to immunise mice against the
cancers from which the fractions were prepared. A number of
proteins have been identified using this approach and a large
proportion of these were found to be related to the hsps.
Given that these proteins are among the most highly
conserved proteins between species throughout evolution, it
is unlikely that they are tumour-specific antigens. Indeed,
comparison of cDNA sequences of gp96 and hsp9o from
heatlhy tissue and antigenically distinct tumours did not
reveal any differences in DNA sequences (Srivastava et al.,
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1991). Moreover, hsps isolated from healthy tissues did not
elicit immunity against any tumours tested, i.e. there did not
appear to be any cross-immunity. There was no tumour
cross-protection, the mice could only be immunised against
the tumour from which the peptides were extracted.
Srivastava and Heike have suggested that hsps may not be
tumour antigens per se but involved in antigen presentation.
Immunisation with hsp gp96, hsp9o or hsp7o isolated from
distinct tumours has been shown to result in specific immune
responses against the homologous tumour (Srivastava et al.,
1986, 1993; Udono and Srivastava, 1993). However, it
appears not to be the hsp itself that causes this immune
response, rather the peptides that are attached to it. This was
demonstrated by the immunisation of mice with either hsp70
derived from MethA sarcoma or hsp70 purified from normal
tissue. The tumour diameter in the mice immunised with
MethA-derived hsp70 showed a considerable reduction unlike
those in mice immunised with normal purified hsp70.
However, when the MethA-derived hsp70 was purified using
ATP affinity chromatography there was no reduction in the
tumour, showing that it is the peptides that are responsible
for this immune response rather than the hsp per se.
Moreover, when the antigenically active MethA-derived
hsp7o was further purified with ATP affinity chromatogra-
phy the purified intact hsp70 remaining was no longer able to
render the mice immune to subsequent challenges. Separation
of the low molecular weight material showed a diverse range
of peptides with molecular masses between 1000 and 5000
daltons. These results suggest that the antigenicity derives,
not from hsp70 per se, but from associated peptides. The
authors conclude that the peptides are derived from cellular
proteins by proteolytic degradation. The authors postulate
that the repertoire ofpeptides generated in the tumour cells is
likely to differ from those generated in normal tissues because
of tumour-associated mutations, which would explain the
difference in antigenicity of tumour compared with normal
tissue-derived hsp70. It is not clear whether the peptide-
binding activity is found in all subsets of the hsp70 family.
Recently, there has been much evidence to indicate that
hsp90, gp96 and hsp70 associate with antigenic peptides
derived from cellular proteins. This has led to two hypotheses
being proposed: (1) that hsps constitute a relay line in which
the peptides, after generation in the cytoplasm by proteases,
are transferred from one hsp to another, until they are finally
accepted by MHC class 1 molecules in the endoplasmic
reticulum; and (2) that the binding of peptides by hsps
constitutes a key step in the priming of cytotoxic T
lymphocytes (CTLs) in vivo. One possibility is the follow-
ing: hsps are released from tumour cells in vivo during lysis of
cells through infection or by the action of antibodies. The
hsps which are now complexed with antigenic peptides
derived from cognate cells are taken up by macrophages or
other specialised antigen-presenting cells. The hsp-borne
peptide is then routed to the endogenous presentation
pathway in the antigen-presenting cell and is displayed in
the context of that cell's MHC class 1, where it is finally
recognised by the precursor CTLs. This mechanism explains
the phenomenon of cross-priming and has implications for
the development of immunological strategies against cancer.
Summary
It is clear therefore that hsps are overexpressed in patients
with malignant tumours compared with healthy controls and
this overexpression does show some correlation with disease
features. Furthermore, expression of hsps has been reported
on the cell surface of tumour cell lines. This could be
associated with the immune response which has been
reported with hsp90 and which also correlates with some
disease features. It now appears that hsps may be involved in
the presentation of tumour antigens leading to the possibility
of hsps being used as a means of therapy. Hsp65 expression
has not been investigated in patients with breast cancer.HOWs no- and breast cancer
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However, transfection of bacterial hsp65 into a tumour cell
line resulted in the hsp65-expressing tumour cells losing their
tumongenicity in mice (Lukacs et al.. 1993). Thus. hsps and
the immune response to them are of interest as diagnostic
and prognostic tools as well as a novel form of
immunotherapy.
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